EMJ Oncology 9 [Supplement 3] . 2021

DURING a satellite symposium at the virtual 17th St Gallen International Breast Cancer Conference 2021, Dr Aleix Prat and Dr Giuseppe Curigliano discussed reimagining treatment of HR+, HER2- early breast cancer (EBC).

They covered important topics such as recurrence risk, the rationale for CDK4/6 inhibitors in EBC and who may benefit from such treatment, and what the future might look like in EBC.